Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs

[Business Wire] – Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has accepted for filing and review three supplemental New Drug Applications for Daklinza , an NS5A replication complex . . . → Read More: Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs Similar Articles: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – CORRECTING and REPLACING Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27 Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S. Market Update (NYSE:BMY): Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen